Molibresib, a targeted drug with a high affinity to bromodomains of BRD4, showed favorable antitumor activity in various GC cells, and the inhibition of BRD4 activity by siRNAs or molibresib could facilitate the chemosensitivity of dasatinib in GC cells. The gene discussed is BRD4; the disease is gastric cancer.